Home › Pain After Surgery › NCT07672808
Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients age 18 and older * Patients who have undergone total hip arthroplasty by a single, fellowship trained Orthopaedic Surgeon. Exclusion Criteria: * Patients with incomplete data in medical records * Chronic opioid use in the last 3 months * Ipsilateral joint surgery in the last year * Cannot tolerate oral medications * Swallowing difficulties * Intolerance to Tylenol, Celebrex, Robaxin, Neurontin, or Tramadol * History of Alcohol abuse * History of Drug abuse * History of Renal impairment * History of Peptic ulcer disease * History of GI bleeding * Illicit narcotic usage in past 6 months * Chronic liver disease * Chronic pain syndrome
About the study
This study examines whether patients undergoing total hip replacement surgery can manage their pain effectively while using fewer opioid pain medications. Participants will be randomly assigned to one of two groups. The first group will receive the standard postoperative pain medication regimen, with all prescriptions sent directly to their pharmacy as usual. The second group will receive the same medications, but their opioid prescription will only be provided as a printed copy rather than being sent directly to the pharmacy, requiring them to choose whether to fill it. All participants will keep a pain journal and complete questionnaires about their medication intake over the first 21 days post-op as well as there function and wellbeing at follow up visits over 3 months. The goal is to determine whether this approach reduces opioid use while still adequately controlling pain after hip replacement surgery.
What is being tested
- Standard Multimodal Analgesic Regimen with Opioid Prescription (drug)
- Opioid-Reduced Multimodal Analgesic Regimen with Printed Prescription (behavioral)
Sponsor: Henry Ford Health System · Participants: 100 · Started: Jul 20, 2026
Contact the study team
- Antonio M Pellerito, BA · Phone: 586-859-3258
Official record on ClinicalTrials.gov — NCT07672808
Locations in the U.S.
| Michigan | Henry Ford Hospital, Detroit |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.